Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Deshpande, Vikram ^a   Nduaguba, Afamefuna ^c   Zimmerman, Stephanie M ^a   Kehoe, Sarah M ^b   MacConaill, Laura E ^b   Lauwers, Gregory Y ^a   Ferrone, Cristina ^a   Bardeesy, Nabeel ^a   Zhu, Andrew X ^a   Hezel, Aram F ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CATENIN; CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LKB1; PROTEIN NRAS; PROTEIN P53; SMAD4 PROTEIN; UNCLASSIFIED DRUG; PIK3CA PROTEIN, HUMAN;

ADENOSQUAMOUS CARCINOMA; AGED; ARTICLE; BILE DUCT CARCINOMA; CELL DIFFERENTIATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GENE MUTATION; HEPATIC DUCT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; MALE; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; ONCOGENE; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA; ADULT; BILE DUCT TUMOR; CARCINOMA; GALLBLADDER TUMOR; GENETICS; INTRAHEPATIC CHOLANGIOCARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA; CHOLANGIOCARCINOMA; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GALLBLADDER NEOPLASMS; GENES, RAS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; VALIDATION STUDIES AS TOPIC;

EID: 79551682846     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-60     Document Type: Article

References (39)

1. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96(6):896-902. 10.1038/sj.bjc.6603648, 2360111, 17325704.
2. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52(5):706-712. 10.1136/gut.52.5.706, 1773624, 12692057.
3. Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, Shen MC, Deng J, Hsing AW. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002, 8(10):3156-3163.
4. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991, 51(13):3497-3502.
5. Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, Matsubara K, Kawasaki Y, Yamamoto S, Kajiyama G. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999, 94(6):1638-1642. 10.1111/j.1572-0241.1999.01155.x, 10364037.
6. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, Wittekind C. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000, 47(5):721-727. 10.1136/gut.47.5.721, 1728101, 11034592.
7. Saetta AA, Papanastasiou P, Michalopoulos NV, Gigelou F, Korkolopoulou P, Bei T, Patsouris E. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004, 445(2):179-182. 10.1007/s00428-004-1046-9, 15221372.
8. Goldenberg D, Rosenbaum E, Argani P, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J, Maitra A. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004, 17(11):1386-1391. 10.1038/modpathol.3800204, 15181454.
9. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006, 12(6):1680-1685. 10.1158/1078-0432.CCR-05-1692, 16551849.
10. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 2005, 131(10):649-652. 10.1007/s00432-005-0016-1, 16032426.
11. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008, 47(5):363-367. 10.1002/gcc.20540, 18181165.
12. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, Schwarte-Waldhoff I, Maschek H, Schmiegel W. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998, 58(6):1124-1126.
13. Ueki T, Hsing AW, Gao YT, Wang BS, Shen MC, Cheng J, Deng J, Fraumeni JF, Rashid A. Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 2004, 10(5):1717-1725. 10.1158/1078-0432.CCR-1137-3, 15014024.
14. Tannapfel A, Weinans L, Geissler F, Schutz A, Katalinic A, Kockerling F, Hauss J, Wittekind C. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 2000, 45(2):317-324. 10.1023/A:1005412626515, 10711445.
15. Suto T, Habano W, Sugai T, Uesugi N, Funato O, Kanno S, Saito K, Nakamura S. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 2000, 73(3):158-163. 10.1002/(SICI)1096-9098(200003)73:3<158::AID-JSO9>3.0.CO;2-N, 10738270.
16. Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, Kim SW, Kim WH, Yoon YB, Kim CY. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001, 169(1):59-68. 10.1016/S0304-3835(01)00562-6, 11410326.
17. McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009, 27(33):5650-5659. 10.1200/JCO.2009.22.9054, 19858389.
18. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096. 10.1200/JCO.2009.21.9170, 19188670.
19. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26(15):2442-2449. 10.1200/JCO.2007.14.8494, 18458038.
20. Brower V. BRAF inhibitors: research accelerates in wake of positive findings. J Natl Cancer Inst 102(4):214-215.
21. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4(11):e7887. 10.1371/journal.pone.0007887, 2774511, 19924296.
22. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39(3):347-351. 10.1038/ng1975, 17293865.
23. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28(21):3531-3540. 10.1200/JCO.2009.27.4787, 20547994.
24. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993, 8(4):312-318. 10.1002/mc.2940080415, 8280380.
25. Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995, 55(12):2511-2515.
26. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7(6):561-573. 10.1016/j.ccr.2005.05.014, 15950905.
27. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12 D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14(12):1351-1356. 10.1038/nm.1890, 2683415, 19029981.
28. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005, 102(10):3788-3793. 10.1073/pnas.0409773102, 553328, 15731348.
29. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000, 275(11):8027-8031. 10.1074/jbc.275.11.8027, 10713122.
30. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, Matsumoto T, Yoshimi N, DiGiovanni J. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001, 61(19):6971-6976.
31. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006, 116(7):1843-1852. 10.1172/JCI27282, 1474816, 16767220.
32. Watanabe H, Date K, Itoi T, Matsubayashi H, Yokoyama N, Yamano M, Ajioka Y, Nishikura K. Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann Oncol 1999, 10(Suppl 4):136-139. 10.1023/A:1008330012536, 10436806.
33. Yanagisawa N, Mikami T, Saegusa M, Okayasu I. More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res 2001, 61(1):19-22.
34. Rashid A, Gao YT, Bhakta S, Shen MC, Wang BS, Deng J, Fraumeni JF, Hsing AW. Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001, 61(8):3406-3409.
35. Chang HJ, Jee CD, Kim WH. Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol 2002, 26(6):758-766. 10.1097/00000478-200206000-00009, 12023580.
36. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995, 109(5):1612-1617. 10.1016/0016-5085(95)90650-9, 7557145.
37. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005, 206(3):356-365. 10.1002/path.1779, 15892172.
38. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001, 91(7):1332-1341. 10.1002/1097-0142(20010401)91:7<1332::AID-CNCR1136>3.0.CO;2-4, 11283934.
39. Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, Goggins M, Yeo CJ, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999, 154(6):1835-1840. 10.1016/S0002-9440(10)65440-5, 1866632, 10362809.